摘要
急性早幼粒细胞白血病（APL）是以早幼粒细胞异常增多、凝血功能异常、表达特征性PML—RARn融合基因、且预后良好为特征的一类独特类型白血病。APL的治疗分为诱导、巩固、维持三个阶段。全反式维甲酸应用于诱导、巩固治疗可提高完全缓解率，改善长期预后，而是否需应用于维持治疗阶段尚存争议；蒽环类药物用于诱导及巩固治疗，可降低早期病死率、改善预后；砷剂不仅可作为复发、难治性APL的二线治疗药物，也可用于新发APL的诱导治疗，且在巩固、维持治疗各个阶段应用砷剂可提高总体生存率、降低复发率；对于复发、难治及晚期APL，造血干细胞移植仍是有效的治疗措施之一。去甲基化药物的出现在未来可能对复发、难治及晚期APL的治疗发挥作用。现就此对APL的治疗新进展作一综述。
出处
《国际输血及血液学杂志》
CAS
2013年第2期127-132,共6页
International Journal of Blood Transfusion and Hematology
参考文献44
-
1Hillestad LK. Acute promyelocytic leukemia. Aeta Med Scand, 1957,159(3) : 189-194.
-
2Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyeloeytic leukaemia. Br J Haematol, 2000, 108(4) :689-695.
-
3Cordonnier C, Vernant JP, Brun B, et at. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer, 1985, 55 (1):18-25.
-
4Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol, 2009, 27 (4): 504-510.
-
5Hu J, Liu YF, Wu CF,et al. Long-term efficacy and safety of all-trans retinoie acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Aead Sci U S A, 2009, 106(9) :3342-3347.
-
6Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyeloeytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol, 2007, 78(3) :213-219.
-
7Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia, 2011, 25(7) :1128-1134.
-
8Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, 2011, 118(5) :1248-1254.
-
9McClellan JS, Kohrt HE, Coutre S, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologiea, 2012, 97 (1) : 133-136.
-
10Frankel SR, Eardley A, Lauwers G, et al. The 'retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med, 1992, 117(4): 292-296.
同被引文献18
-
1张之南.血液病诊断及疗效标准[M].3版.北京:科学出版社,2008:1.
-
2O' DotmeU MR, TaUman MS, Abboud CN, et al. Acutey myeloid leukemia, Version 2. 2013: Featured Updates to the NCCN Guide- lines[J]. J Nat1 Compr Canc Netw, 2013, 11 (9) : 1047 -1055.
-
3Seftel MD, Barnett MJ, Couban SA, et al. Candian consensus on the management of newly diagnosed and relapsed acute premyelocyt- ic leukemia [ J]. Curr ancol, 2014, 21 (5) : 234 - 250.
-
4Watts JM, Tailman MS. Acute promyelocytic leukemia: what is the new standard of care .9 [ J ]. Blood Rev, 2014, 28 (5) : 205 - 212.
-
5Dekking EHA, van der Velden VH, Varro R, et al. Flow cytomet- ric immunobead assay for fast and easy detection of PML - RARA fusion proteins for the diagnosis of acute promyelocytic leukemia [J]. Leukemia, 2012, 26(9) : 1976 - 1985.
-
6Massimo B, Francesco LC. Thrombo- hemorrhagic deaths in acute promyelocytic leukemia[ J]. Thrombosis Res, 2014, 133 ( Suppl 2) : 112 -116.
-
7Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all - transretinoic acid [J]. Blood, 2011, 118(5): 1248 -1254.
-
8Altman JK, R ademaker A, Cull E, et al. Administration of ATRA to newly diagnosed patients with acute premyeloeytie leukemia is de-layed contributing to early hemorrhagic death [ J ]. Leuk Res, 2013, 37(9) : 1004 -1009.
-
9Stein EM, Tallmana MS. Acute promyelocytic leukemia in children and adolescents [ J]. Acta Haematol, 2014, 132 (3/4) : 307 - 312.
-
10Rego EM, Kim HT, Ruiz - Argilelles GJ, et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the international consortium on APL [J]. Blood, 2013, 121(11): 1935-1943.
-
1杜丰,袁芃,罗杨,王佳玉,马飞,蔡锐刚,樊英,李青,张频,徐兵河.长春瑞滨为基础的联合化疗用于蒽环类和紫杉类药物失败后晚期三阴性乳腺癌的疗效及安全性[J].中华肿瘤杂志,2015,37(10):788-792. 被引量：8
-
2马天江,张国耀,陈素华,张智慧.长春瑞滨联合顺铂治疗蒽环类治疗失败的晚期乳腺癌临床观察[J].中国肿瘤临床与康复,2008,15(4):366-367. 被引量：2
-
3白颖,翟明.急性白血病巩固治疗阶段应用亚砷酸1例[J].白血病．淋巴瘤,2003,12(2):125-126.
-
4楼晓清,应茵.吉非替尼与多西他赛治疗非小细胞肺癌比较的Meta分析[J].浙江中西医结合杂志,2015,25(6):610-613. 被引量：2
-
5钟巍,王孟昭,张力,张晓彤,李龙芸.吉非替尼与多西紫杉醇二线治疗晚期非小细胞肺癌[J].肿瘤学杂志,2009,15(6):508-511. 被引量：4
-
6张葛,卢雯萍,贺用和,花宝金,林洪生.舒尼替尼二线治疗晚期肾透明细胞癌1例[J].临床肿瘤学杂志,2015,20(12):1149-1150.
-
7吕丽艳,王文静,宋悦.蛋白质组学在肝癌中的研究进展[J].齐齐哈尔医学院学报,2008,29(7):847-848.
-
8韩冬梅.浅谈上消化道恶性肿瘤化疗的研究进展[J].世界最新医学信息文摘,2016,0(32):37-37.
-
9徐岚,陈芳源,黄洪晖,钟华,钟璐,沈莉菁,朱坚轶,韩洁英,陈冰.三氧化二砷治疗初治急性早幼粒细胞白血病疗效分析[J].白血病．淋巴瘤,2010,19(11):651-654. 被引量：3
-
10陈少华,邱前辉.雄激素受体与鼻咽纤维血管瘤的关系[J].实用医学杂志,2001,17(10):956-957.
